Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Scientists Search For Sleepless Souls Suffering Lifelong Insomnia, Scotland
Most people have experienced the odd sleepless night before a crucial exam, a job interview or before going on holiday, but few people get by with just a couple of hours of sleep a day, every day.

What Is The Difference Between Hip Resurfacing And Total Hip Replacement?
If hip resurfacing is an option, the surgeon will simply reshape the damaged surface of the femoral ball and then cover it with a round metal cap. The limitation here is that the procedure only works for bone that is not too damaged by arthritis. Generally speaking, surface replacements are not performed on patients with serious arthritic conditions, because if the bone is not strong enough, there is a small but real risk of fracturing. Therefore the average age of resurfacing patients may be 50 years or younger. Statistically, the resurfacing operation is an option for about 7 out of a 100 patients.
News of the day
Early Screening Reduces Disparities For Prostate Cancer
Men who have a regular, ongoing relationship with a health care provider are more likely to receive prostate cancer screening and less likely to be diagnosed with advanced prostate cancer, regardless of their race, according to a University of North Carolina study published in the current issue of the journal Cancer.
Sexual Health

Ridge Diagnostics, Inc. Clinical Data On Blood Test For Depression Presented At American Psychiatric Association Annual Meeting

Ridge Diagnostics, Inc., a neurodiagnostic company, announced that data from clinical studies for its first-in-class, proprietary blood test for Major Depressive Disorder(MDD), will be presented during a poster session entitled Multianalyte Biomarker Blood Test to Aid in Diagnosis, Treatment and Management of Major Depressive Disorder, at the American Psychiatric Association Annual Meeting, May 20, 2009. The blood test, for the first time, provides clinicians with biological information derived from physiological changes associated with MDD. By adding an objective, biological basis, the blood test results are intended to augment the paradigm used for neuropsychiatric diagnosis and patient management, primarily clinical interviews. Our approach differs from other investigators seeking to utilize single or groups of single biomarkers to characterize or identify patients with MDD by use of multiple markers and the construction of a unique diagnostic hyperspace mapping technology. "We are pleased to present this clinically important blood test to the psychiatric community at the APA meeting," stated Stan Sewitch, President and CEO of Ridge. "We believe the assay results provide an objective adjunct to a patient"s diagnosis and management, while at the same time providing the research community with a valuable tool for optimization of studies." The poster will be presented by Dr. Perry Renshaw, Chief Medical Officer of Ridge Diagnostics and Director of Magnetic Resonance, Utah Brain Institute, Professor of Psychiatry, University of Utah School of Medicine. Ridge Diagnostics, Inc. is a neurodiagnostic company commercializing a breakthrough, first-in-class, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD). The company"s products are derived from a proprietary Human Biomarker Library(TM) and Biomarker Hyper-mapping (BHyperMap(TM) )technology. Ridge intends to develop a comprehensive neuropsychiatric disease diagnostic platform. Ridge Diagnostics testing services are provided through its CLIA certified laboratory in North Carolina, and it is developing a kit version for future distribution. The company is located in San Diego, CA and Research Triangle Park, NC. Ridge Diagnostics, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009